TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants who identify study components as acceptable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment emergent adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of subjective satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of objective satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy intake (kcal) during ad libitum lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective tumor response according to GOG RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency and severity of adverse events as assessed by CTCAE v 3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Global Impressions - severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time In Range (TIR, 70-180 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal Clearance (CLR) of AG-881
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AG-881
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-∞) of AG-881
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean effectiveness of NEM® in relieving general pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for other postoperative analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Subjects Achieving Desired Peak FVIII Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Freedom From Death and Mitral Regurgitation (MR) >2+
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Measures of Benefit-Quality of Life (QOL) as Measured by Short Form (SF) 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall subjective acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax,ss of Celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of DWP14012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of DWP14012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of Naproxen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of Naproxen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testosterone serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thromboembolic or major bleeding complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intestinal inflammation measured by fecal calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sleep Times
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Vagal Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Mental State Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail Making Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Color Trail Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rivermead Behavioral Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Contextual Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity and specificity of the POC test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Erythropoetin and ATRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time until analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal isometric strength of quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee flexion range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recall of key information about EMA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: repeatability of test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day composite of major adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of craniosynostosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross total resection (GTR) achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients returning to independent functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Evoked Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of total responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant changes in 12-lead ECG (electrocardiogram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Moderate (or Higher) Physical Activity Duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Leads Free From Complication (0 - 3 Months)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Leads Free From Complication (3 - 24 Months)
Endpoint domain: Adverse events/effects
Primary endpoint: Hazard Rate of Lead-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Acute Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Effects
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of venous thromboembolism (VTE) events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of major and clinically relevant bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain NRS change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total brain atrophy on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: response to treatment with bevacizumab based on Ang1 and Tie2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response to treatment with bevacizumab based on VEGF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of viable injected cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to make spheres (cluster of cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of spheres to the amount of injected cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving at least a 75% reduction in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Major adverse clinical events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of ADHD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained Virologic Response at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in medical regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downstream cardiovascular testing and hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline Social-Emotional Competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Bullying Prevalence (self-report)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline Bullying Prevalence (objective)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Decayed, Missing, Filled Surfaces (DMFS) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Simplified Oral Hygiene Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Modified Gingival index from the Community Periodontal Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Uroflow curve pattern - Clinical assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Uroflow curve pattern - Mathematical assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of hydroxychloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Antibiotic Exposure Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Any Adverse Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in time of spontaneous scratching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Area Under the Curve) for T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in COPD assessment Test (CAT Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate visualization of the uterine cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Vigilance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Hypervigilance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Buckpassing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Procrastination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Physical power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Laboratory Abnormalities Based on Hematology, Clinical Chemistry, Coagulation and Urinalysis Test Results
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Abnormalities in Electrocardiograph (ECG) Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Abnormalities in Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Bactericidal Activity Against MenC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Antibody Titers Against Haemophilus Influenzae Type b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: uterine contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Biomarker levels in serum, cerebrospinal fluid and parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the device characterized by reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with major adverse cardiovascular events (MACEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: INR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC of prothrombin and INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Size of right internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Amount of blood products transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tinetti Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go (TUG) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical College of Virginia (MCV) Gait Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental and psychomotor development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: serum levels of albumin-bound substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Redo surgery for valve dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Moderate-severe or severe mitral regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-prandial blood glucose excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients free of disease at 24 months post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Time to recurrence after liver transplant
Endpoint domain: Mortality/survival
Primary endpoint: Subjective experience of radiculopathic pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Swallowing amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Satisfaction with Normal Delivery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived readiness for discharge VAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in cardiometabolic health markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants who are newly diagnosed with HIV at enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in viral load among HIV-infected participants who initiate HAART during their study participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in STI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Health related Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CRS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain scores in the neck region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glomerular Filtration Rate (inulin clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proteinuria (albumin to creatinine ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Toxicities Experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Renal Artery Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Gut microbiome features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ACR20 score at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BODY FAT PERCENTAGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WAIST AND HIP CIRCUMFERENCES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WIDEA Neurodevelopmental Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Post-neonatal Epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Appropriateness of Decision to Treat or Not Treat With Thrombolytics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase of the measuring index visuospatial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Output of C13-CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: free survival
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the amount of mesenchymal stromal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risky drinking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of laparoscopic sentinel lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean change in sleep onset latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: NRS of low back pain (LBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS of radiating leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS of neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS of radiating arm pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS of knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS of shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distinguishing adenomatous polyps with malignant potential from non-neoplastic polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Effects
Endpoint domain: Adverse events/effects
Primary endpoint: functional recruitment of capillaries in the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in score on Kidney Disease Quality of Life Short Form 36 (KDQOL-36™)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage change in LDL-Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trough plasma concentration at steady state (Cmin,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from 0 to 12 hours (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychopathology changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ezogabine/retigabine and NAMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum neuroinflammatory marker concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aphasia Quotient (WAB-AQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Mayo Portland Adaptability Inventory (MPAI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Study Defined Grade 3 or Higher Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Liver Transplant Recipients Who Are Able to Reduce Calcineurin Inhibitor Dosing by 75 Percent and Discontinue a Second Immunosuppression Drug With Stable Liver Function Tests for ≥ 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of CD4+ T Cell Responses to the HIV Proteins Included in the Vaccine After the Primary Vaccine Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 28-days mortality
Endpoint domain: Mortality/survival